Companies /Healthcare

Bio-Rad Laboratories Inc - Class A

NYSE: BIO Medical Devices
$370.17
▲ $11.98 (+3.34%) today
Markets closed · 12:34am ET

24/7 Wall St. View

BIO at a Glance

Valuation
Market cap
$9.6B
P/E ratio
9.6
Profitability
Revenue (TTM)
$2.6B
Profit margin
39.5%
EPS (TTM)
$37.42
Price
52-week range
$237 – $396
24/7 target
$441.32
Street target
$356.67
Earnings
Next report
Feb 10, 2027

Headquartered in Hercules, CA Fiscal year ends December NYSE: BIO bio-rad.com

About Bio-Rad

Bio-Rad Laboratories develops, manufactures and markets a broad range of products for the life science research and clinical diagnostics markets, through two reporting segments.

- **Clinical Diagnostics (about 61% of Q3 2026 sales):** quality systems (quality control products) and diabetes testing products for hospitals and clinical laboratories.
- **Life Science (about 39%):** research tools including Droplet Digital PCR systems, ChemiDoc imaging systems, and process chromatography resins and pre-packed columns (Nuvia, Foresight Pro) used in biopharmaceutical manufacturing.

Customers include universities, research institutions, hospitals, biopharmaceutical companies, and clinical, food safety and environmental quality laboratories. Sales are spread across the Americas, EMEA and Asia Pacific. The company employed approximately 7,100 people and generated $2.6 billion in revenue in 2025.

Bio-Rad holds a significant equity investment in Sartorius AG, whose fair value changes materially swing reported GAAP earnings. It is currently executing a transformation program that includes restructuring and reprioritization of R&D programs. Updated

BIO Coverage

Frequently Asked Questions

What does Bio-Rad do?

Bio-Rad Laboratories develops, manufactures and markets a broad range of products for the life science research and clinical diagnostics markets, through two reporting segments. - **Clinical Diagnostics (about 61% of Q3 2026 sales):** quality systems (quality control products) and diabetes testing products for…

What is the BIO stock price target?

24/7 Wall St.'s 12-month price target for BIO is $441.32, rated Buy. The Wall Street consensus target is $356.67. BIO price prediction →